Justin J Baker1, Michael O Meyers1, Jill Frank1, Keith D Amos1, Karyn B Stitzenberg1, David W Ollila2. 1. Division of Surgical Oncology and Endocrine Surgery and The Lineberger Comprehensive Cancer Center, Department of Surgery, University of North Carolina at Chapel Hill, Campus Box 7213, 170 Manning Drive, 1150 POB, Chapel Hill, NC 27599, USA. 2. Division of Surgical Oncology and Endocrine Surgery and The Lineberger Comprehensive Cancer Center, Department of Surgery, University of North Carolina at Chapel Hill, Campus Box 7213, 170 Manning Drive, 1150 POB, Chapel Hill, NC 27599, USA. Electronic address: david_ollila@med.unc.edu.
Abstract
BACKGROUND: Follow-up of patients with sentinel lymph node-positive stage III melanoma uses history, physical exam, and cross-sectional imaging. The aim of this study was to evaluate positron emission tomographic (PET)/computed tomographic (CT) scans in the detection of recurrence. METHODS: From 2003 to 2009, a single-institution prospective database of all cutaneous melanoma patients was used to identify sentinel lymph node-positive stage III patients with disease-free survival >1 year and 1 restaging PET/CT scan. RESULTS: Thirty-eight patients were identified, with a median follow-up period of 27.5 months. Seven (18%) developed recurrence (median time to recurrence, 25 months). Recurrences were detected as follows: 3 by patients, 1 by physician, 1 by PET/CT scan and lactate dehydrogenase, 1 by PET/CT scan, and 1 by brain magnetic resonance imaging. One hundred eight follow-up PET/CT scans were performed. Two of 38 patients had asymptomatic metastases detected by routine restaging PET/CT scan, and there were 9 scans with false-positive results. CONCLUSIONS: With short follow-up, the utility of routine PET/CT scans in identifying unsuspected recurrence in patients with sentinel lymph node-positive stage III melanoma appears minimal.
BACKGROUND: Follow-up of patients with sentinel lymph node-positive stage III melanoma uses history, physical exam, and cross-sectional imaging. The aim of this study was to evaluate positron emission tomographic (PET)/computed tomographic (CT) scans in the detection of recurrence. METHODS: From 2003 to 2009, a single-institution prospective database of all cutaneous melanomapatients was used to identify sentinel lymph node-positive stage III patients with disease-free survival >1 year and 1 restaging PET/CT scan. RESULTS: Thirty-eight patients were identified, with a median follow-up period of 27.5 months. Seven (18%) developed recurrence (median time to recurrence, 25 months). Recurrences were detected as follows: 3 by patients, 1 by physician, 1 by PET/CT scan and lactate dehydrogenase, 1 by PET/CT scan, and 1 by brain magnetic resonance imaging. One hundred eight follow-up PET/CT scans were performed. Two of 38 patients had asymptomatic metastases detected by routine restaging PET/CT scan, and there were 9 scans with false-positive results. CONCLUSIONS: With short follow-up, the utility of routine PET/CT scans in identifying unsuspected recurrence in patients with sentinel lymph node-positive stage III melanoma appears minimal.
Authors: David Y Lee; Briana J Lau; Kelly T Huynh; Devin C Flaherty; Ji-Hey Lee; Stacey L Stern; Steve J O'Day; Leland J Foshag; Mark B Faries Journal: J Am Coll Surg Date: 2016-01-29 Impact factor: 6.113
Authors: Jacqueline Dinnes; Lavinia Ferrante di Ruffano; Yemisi Takwoingi; Seau Tak Cheung; Paul Nathan; Rubeta N Matin; Naomi Chuchu; Sue Ann Chan; Alana Durack; Susan E Bayliss; Abha Gulati; Lopa Patel; Clare Davenport; Kathie Godfrey; Manil Subesinghe; Zoe Traill; Jonathan J Deeks; Hywel C Williams Journal: Cochrane Database Syst Rev Date: 2019-07-01
Authors: Martine Bloemendal; Wouter W van Willigen; Kalijn F Bol; Marye J Boers-Sonderen; Johannes J Bonenkamp; J E M Werner; Erik H J G Aarntzen; Rutger H T Koornstra; Jan Willem B de Groot; I Jolanda M de Vries; Jacobus J M van der Hoeven; Winald R Gerritsen; Johannes H W de Wilt Journal: Ann Surg Oncol Date: 2019-03-04 Impact factor: 5.344